Skip to main content
. Author manuscript; available in PMC: 2024 Nov 1.
Published in final edited form as: Gynecol Oncol. 2023 Sep 23;178:27–35. doi: 10.1016/j.ygyno.2023.09.010

Figure 2.

Figure 2.

Oncologic outcomes by starting lenvatinib dose (standard vs low dose). A) rogression-free survival; B) Overall survival; and C) Duration of response.

DOR=duration of response; NE=not evaluable; OS=overall survival; PFS=progression-free survival.